Daclatasvir Daklinza
Elbasvir-Grazoprevir Zepatier
Glecaprevir-Pibrentasvir Mavyret
Ledipasvir-Sofosbuvir Harvoni
Ombitasvir-Paritaprevir-Ritonavir Technivie
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir Viekira Pak
Peginterferon alfa-2a Pegasys
Peginterferon alfa-2b PegIntron
Ribavirin Copegus, Rebetol, Ribasphere
Simeprevir Olysio
Sofosbuvir Sovaldi
Sofosbuvir-Velpatasvir Epclusa
Sofosbuvir-Velpatasvir-Voxilaprevir VoseviSection Navigation
Section Navigation
- Section 4 Overview
Evaluation and Preparation for Hepatitis C Treatment - 0%Topic 1
Goals and Benefits with HCV TreatmentActivities- 0%Topic 2
Making a Decision on When to Initiate HCV TherapyEvaluation and Preparation for Hepatitis C Treatment Overview
Section Core Competency
Provide Evidence-Based Evaluation and Preparation for Treatment of Persons with Hepatitis C Infection
Target Audience
For clinicians evaluating persons with chronic HCV infection for hepatitis C treatment, including clinicians who will independently assess treatment candidacy and clinicians who will provide treatment candidacy with assistance from a hepatitis C expert.Editors
John D. Scott, MD,John D. Scott, MD
Assistant Director Hepatitis and Liver Clinic
Harborview Medical Center
Associate Professor of Medicine
Division of Infectious Diseases
University of WashingtonDisclosures: Consulting: NovartisDavid H. Spach, MDDavid H. Spach, MD
Professor of Medicine
Division of Infectious Diseases
University of WashingtonDisclosures: NoneFree CE CNE/CME
Section Topics
1Topic 1 Goals and Benefits with HCV Treatment
- Learning Objectives
- Discuss the goals and rationale for hepatitis C therapy with patients considering treatment.
- Predict a patient's response to treatment for chronic hepatitis C infection based on specific host and viral factors.
- Quick ReferenceGoals and Benefits with HCV Treatment Core Concepts
- Self-Study CNE/CMEGoals and Benefits with HCV Treatment Lesson
2Topic 2 Making a Decision on When to Initiate HCV Therapy
- Learning Objectives
- Reflect on the indications, contraindications, and patient readiness when considering initiating hepatitis C therapy.
- Integrate knowledge of new medications when considering the timing of initiating hepatitis C therapy.
- Quick ReferenceMaking a Decision on When to Initiate HCV Therapy Core Concepts
- Self-Study CNE/CMEMaking a Decision on When to Initiate HCV Therapy Lesson
3Topic 3 Cost and Access to Direct-Acting Antiviral Agents
- Learning Objectives
- Summarize the costs of direct-acting antiviral agents used to treat hepatitis C.
- Describe major steps in accessing new direct-acting antiviral medications used to treat hepatitis C.
- Quick ReferenceCost and Access to Direct-Acting Antiviral Agents Core Concepts
- Self-Study CNE/CMECost and Access to Direct-Acting Antiviral Agents Lesson
4Topic 4 Addressing Adherence Prior to Initiating HCV Treatment
- Learning Objectives
- List different methods to measure patient adherence when receiving hepatitis C therapy.
- Identify barriers to adherence and discuss strategies that can maximize adherence.
- Quick ReferenceAddressing Adherence Prior to Initiating HCV Treatment Core Concepts
- Self-Study CNE/CMEAddressing Adherence Prior to Initiating HCV Treatment Lesson
Share by e-mail
Check
-On-
Learning
QuestionsThe Check-on-Learning Questions are short and topic related. They are meant to help you stay on track throughout each lesson and check your undestanding of key concepts.You must be signed in to customize your interaction with these questions.
- 0%Topic 2
Funded through a Centers for Disease Control and Prevention Cooperative Agreement (CDC-RFA- PS16-1608)
CME provided byUniversity of Alabama Birmingham
- HCV Medications
- Daclatasvir (Daklinza)
- Elbasvir-Grazoprevir (Zepatier)
- Glecaprevir-Pibrentasvir (Mavyret)
- Ledipasvir-Sofosbuvir (Harvoni)
- Ombitasvir-Paritaprevir-Ritonavir (Technivie)
- Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir (Viekira Pak)
- Peginterferon alfa-2a (Pegasys)
- Peginterferon alfa-2b (PegIntron)
- Ribavirin (Copegus, Rebetol, Ribasphere)
- Simeprevir (Olysio)
- Sofosbuvir (Sovaldi)
- Sofosbuvir-Velpatasvir (Epclusa)
- Sofosbuvir-Velpatasvir-Voxilaprevir (Vosevi)
- Course Modules
- Slide LecturesCore ConceptsMaster Bibliography
ContributorsContent Bundles - Clinical Calculators
Copyright © 2019 Hepatitis C Online
Since you've received 80% or better on this quiz, you may claim continuing education credit.
You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.
Current Version: 2.7.0